AUPH

Aurinia Pharmaceuticals Inc.

A biopharmaceutical company in Victoria, British Columbia, that develops and sells treatments for autoimmune diseases. Its signature drug, LUPKYNIS (voclosporin), is an oral medicine for adults with lupus nephritis, a kidney inflammation caused by lupus. The company began in 1993 in Edmonton as Isotechnika Pharma, then took the Aurinia name in 2013 when it acquired Aurinia Pharma Corp. and refocused on voclosporin; the drug won US approval in 2021. The brand name Lupkynis blends "lupus" with a distinctive suffix, and "Aurinia" also names a golden-flowered garden plant called basket of gold.

CUSIP: 05156V102HealthcareCA1 holder

Ownership Activity Financials Filings

AUPH

AUPH

Other Events

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Completion of Acquisition or Disposition of Assets

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Results of Operations and Financial Condition